Serum Prolactin Levels in Behçet’s Disease. Is There a Relationship between Behçet’s Disease and Prolactin as in Other Autoimmune Diseases?

Behçet’s disease (BD) is a multi-system disorder (etiologically unknown) presenting with oral and genital aphthae, arthritis, cutaneous lesions, eye lesions and central nervous system involvement. Although found worldwide, it is mostly reported in Turkey and Japan, followed by Middle East and Mediterranean area as other regions according to its prevalence (1,2). Diagnosis is made clinically. In addition to recurrent aphthous ulceration, at least two symptoms of recurrent genital ulceration, typical eye lesions, typical dermatologic lesions, and positive pathergy test are needed for BD diagnosis. There is no specific laboratory test (3). In its etiology, many factors have been postulated, such as heredity, autoimmunity, infective agents and inflammatory mediators. BD tends to manifest in autoimmune disorders. Prolactin is a prehypophysis hormone considered to be strongly related to autoimmunity. Supported by many researches, prolactin can accompany the progress of some autoimmune diseases (systemic lupus erythematosus, uveitis, rheumatoid arthritis, multiple sclerosis, autoimmune thyroiditis, psoriatic arthritis, etc.) and it can also arise in some autoimmune diseases. In the light of these ideas, we studied whether there is a relationship between BD and serum prolactin level, and compared it with similar studies reported in the literature.

Study group included 43 BD patients, 21 (48.8%) female and 22 (51.2%) male. Control group had included 20 healthy subjects, 11 (55%) female and 9 (45%) male. There was no sex difference between the patient and control groups (p=0.941). The mean prolactin level was 11.63 ng/mL in BD group and 10.19 ng/mL in control group, yielding no significant between-group difference in the mean prolactin level (t=1.272; p=0.264).

The mean serum prolactin level in BD patients was 11.6 ng/mL; 9.84 ng/mL in female and 9.27 ng/mL in...
male BD patients. The mean serum prolactin level in the healthy control group was 8.24 ng/mL; t-test produced no statistically significant difference between the BD patient group and control group. However, although there was no statistically significant difference, higher prolactin levels were measured in the group of BD patients as compared with control group. On the contrary, there are study reports on high serum prolactin levels in BD. In their study, Proença et al. from Portugal showed the mean serum prolactin levels to be significantly higher in BD patients as compared with control group (19.34 ng/mL vs. 9.83 ng/mL) (4). Our results are similar to those reported in the literature. However, additional studies are needed to clarify the issue. We believe that future in-depth research should identify these differences as being significant or nonsignificant.

References


Atıl Avcı¹, Deniz Avcı²

¹Department of Dermatology, ²Department of Internal Medicine, Kayseri Training and Research Hospital, Kayseri, Turkey

Corresponding author:
Atıl Avcı, MD
Department of Dermatology
Kayseri Training and Research Hospital
Kayseri
Turkey
atalavci@hotmail.com

Received: January 12, 2012
Accepted: November 22, 2012